Exscientia Ltd.

78 articles with Exscientia Ltd.

• Exscientia Business and Financial Update for the Full Year 2022

  3/23/2023

  Exscientia plc. Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.

• Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

  3/16/2023

  Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets.

• Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR

  3/15/2023

  Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.

• Exscientia Announces Expansion of its Precision Oncology Pipeline

  3/14/2023

  Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor.

• Exscientia to Present at Upcoming Investor Conferences in March

  2/22/2023

  Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.

• Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

  2/2/2023

  Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

• 

  Voyager's Al Sandrock, Alnylam's Yvonne Greenstreet and More Share Their Predictions for 2023

  12/23/2022

  BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.

• Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress

  12/6/2022

  Exscientia plc (Nasdaq: EXAI) today highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21546 (‘546) as well as the relationship to potential impact of adenosine on PD-1 inhibitor response.

• Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

  11/28/2022

  Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country.

• Exscientia Business and Financial Update for the Third Quarter 2022

  11/15/2022

  Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m. ET.

• Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

  11/14/2022

  Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

• Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022

  11/8/2022

  Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets.

• Exscientia Expands Biologics Design Capability with Automated Laboratory

  11/3/2022

  Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include the design of biologics, such as human antibodies.

• Exscientia to Present at Upcoming Investor Conferences in November

  11/1/2022

  Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November.

• Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium

  10/26/2022

  Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium.

• Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes

  9/20/2022

  Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder.

• 

  Movers & Shakers: Homology Medicines, GlycoMimetics, MiMedx and More Tap New Execs

  9/9/2022

  Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.

• Exscientia to Present at Upcoming Investor Conferences in September 2022

  9/7/2022

  Exscientia announced that Company management will participate in the following investor conferences in September.

• Exscientia Business Update for Second Quarter and First Half 2022

  8/17/2022

  Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.

• Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022

  8/10/2022

  Exscientia will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close.